- Home
- CSTL vs PHLT Comparison
CSTL vs PHLT Comparison
Compare CSTL & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- PHLT
- Stock Information
- Founded
- CSTL 2007
- PHLT 1976
- Country
- CSTL United States
- PHLT United States
- Employees
- CSTL N/A
- PHLT N/A
- Industry
- CSTL Medical Specialities
- PHLT Other Consumer Services
- Sector
- CSTL Health Care
- PHLT Consumer Discretionary
- Exchange
- CSTL Nasdaq
- PHLT Nasdaq
- Market Cap
- CSTL 697.9M
- PHLT 601.2M
- IPO Year
- CSTL 2019
- PHLT N/A
- Fundamental
- Price
- CSTL $21.62
- PHLT $7.69
- Analyst Decision
- CSTL Strong Buy
- PHLT Buy
- Analyst Count
- CSTL 6
- PHLT 2
- Target Price
- CSTL $37.67
- PHLT $7.88
- AVG Volume (30 Days)
- CSTL 423.4K
- PHLT 1.2M
- Earning Date
- CSTL 11-03-2025
- PHLT 11-05-2025
- Dividend Yield
- CSTL N/A
- PHLT N/A
- EPS Growth
- CSTL N/A
- PHLT N/A
- EPS
- CSTL N/A
- PHLT N/A
- Revenue
- CSTL $346,269,000.00
- PHLT $137,357,000.00
- Revenue This Year
- CSTL N/A
- PHLT $12.38
- Revenue Next Year
- CSTL N/A
- PHLT $10.09
- P/E Ratio
- CSTL N/A
- PHLT N/A
- Revenue Growth
- CSTL 20.40
- PHLT 15.21
- 52 Week Low
- CSTL $14.59
- PHLT $2.17
- 52 Week High
- CSTL $35.84
- PHLT $7.74
- Technical
- Relative Strength Index (RSI)
- CSTL 50.19
- PHLT 81.89
- Support Level
- CSTL $22.54
- PHLT $7.56
- Resistance Level
- CSTL $24.74
- PHLT $7.67
- Average True Range (ATR)
- CSTL 1.14
- PHLT 0.03
- MACD
- CSTL -0.28
- PHLT -0.11
- Stochastic Oscillator
- CSTL 28.93
- PHLT 91.67
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.